Amphastar Pharma (NASDAQ: AMPH) reported Q3 EPS of $0.96, $0.04 worse than the analyst estimate of $1.00. Revenue for the quarter came in at $191.2 million versus the consensus estimate of $194.69 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.